COVID-19 Clinical Trial
— REMEDYOfficial title:
Post COVID REspiratory Mechanisms and the Efficacy of a Breathing Exercise Intervention for DYsregulated Breathing (REMEDY): COVID-19
Verified date | June 2024 |
Source | University of Nottingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A pilot Study To investigate the efficacy of a breathing intervention for improving persistent breathlessness due to dysregulated breathing following COVID-19 when compared to usual care.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | July 30, 2024 |
Est. primary completion date | July 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Either hospitalised or non-hospitalised with confirmed COVID-19 acute infection. - Received a comprehensive clinical respiratory assessment - Persisting (>12 weeks) self-reported breathlessness (on CRQ-D) following COVID-19 and confirmed dysregulated breathing (Nijmegen Questionnaire score NQ >23) - Age 18 - 80 years of age - Ability to give informed consent - Able to understand and speak English language Exclusion Criteria: - Severe mood disturbance that limits engagement with the intervention and study outcomes - No access to online delivery and/or IT illiterate - Significant diagnosed Myalgic Encephalitis/Fibromyalgia/Chronic Fatigue Syndrome prior to developing COVID-19 - Severe asthma or other chronic lung disease prior to COVID-19 |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Nottingham University Hospitals Trust | Nottingham | Notts |
Lead Sponsor | Collaborator |
---|---|
University of Nottingham |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Breathlessness. | Chronic Respiratory Disease Questionnaire - Dyspnoea Domain Range 1-7 with lower - worse | 7 weeks | |
Primary | Function | 5 repetition chair to stand. Range 0-120 seconds with longer worse | 7 weeks | |
Secondary | Dyspnoea-12 Questionnaire | SOB questionnaire. Range 0-36, Greater, worse | 7 weeks | |
Secondary | Nijmegen Questionnaire | Measure of dysregulated breathing. 0-64. Greater worse | 7 weeks | |
Secondary | Borg Scale of Breathlessness | Measure of breathlessness. Range 0-10. Greater worse | 7 weeks | |
Secondary | Four metre Gait speed | field test of physical performance. Range 0-60seconds. Greater worse | 7 weeks | |
Secondary | Modified Minnesota Physical Activity | Questionnaire. Range 0-100. Greater better. | 7 weeks | |
Secondary | Capnography - in some volunteers | End tidal CO2 measure in breath - at rest. Range N/A | 7 weeks | |
Secondary | Chalder Fatigue Score | Questionnaire. Range 0-33. Greater worse | 7 weeks | |
Secondary | EQ5D Quality of Life score | Questionnaire. VAS 0-100. Greater is better. | 7 weeks | |
Secondary | Adherence | Recorded from number of potential sessions. Range 0-12. Greater better. | 7 weeks | |
Secondary | Breath hold, Respiratory rate | Observational measures at rest. Breath hold - 0-45. Greater better. RR. Range 0-30. Greater worse | 7 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|